← Back to all signals
RESEARCH PAPER ANALYSIS

[Survival analysis in hepatitis C cases aged ≥18 years in Yuxi City from 2005 to 2023].

AI interpretation is pending for this paper.

Open original publication →
PMID40829906
JournalZhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]
Publication Date2025-08-06
Ingested2026-08-02 12:05 AM
EXECUTIVE SUMMARY

What the AI sees

Not AI summarized yet.

WHY IT MATTERS

Research significance

Pending deeper interpretation.

ABSTRACT

Source abstract

To analyze all-cause mortality among hepatitis C cases aged ≥18 years in Yuxi City from 2005 to 2023 and explore the interactions of factors influencing survival time. Baseline and follow-up data for hepatitis C cases reported during this period were extracted from the Chinese National Notifiable Disease Reporting System. Survival time and related factors were assessed using the Cox proportional hazards model. Kaplan-Meier cumulative mortality risk curves were generated for treated and untreated hepatitis C cases, and interactions among subgroups of various influencing factors were examined. A total of 5 110 hepatitis C cases aged ≥18 years were reported from 2005 to 2023, encompassing 35 349.25 person-years of observation with the follow-up time duration M (Q1, Q3) was 6.17 (2.33, 11.08) person-years. There were 763 all-cause deaths, corresponding to a mortality density of 2.16 per 100 person-years. Survival analysis showed a statistically significant difference in cumulative mortality between the treated and untreated groups (Log-rank χ2=122.033, P<0.001), with a lower risk of death observed among treated patients. Additive model analysis showed that there was a synergistic interaction between treatment status and age group, with relative excess of interaction, attributable proportions of interaction, and synergy index of 6.16 (95%CI: 2.70-9.61), 1.83 (95%CI: 1.46-2.30), and 0.42 (95%CI: 0.31-0.53), respectively; and between treatment status and gender. There was a synergistic interaction between treatment status and sex, with relative excess of interaction, attributable proportions of interaction, and synergy index of 2.63 (95%CI: 1.14-4.13), 1.56 (95%CI: 1.19-2.06), and 0.32 (95%CI: 0.17-0.46), respectively. The cause of death composition were 38.53% (249 cases) attributed to hepatitis C-related causes.The leading non-hepatitis C-related causes of death were cardiovascular and cerebrovascular diseases, pulmonary diseases, malignancies, drug overdose, and injuries. In conclusion, hepatitis C cases ≥18 years of age in Yuxi City had a lower cumulative mortality rate when treated than when untreated. Treatment status interacted with age and gender on patient survival, respectively. Changes in patients with concomitant cardiovascular diseases, pulmonary diseases and malignancies should be focused.

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 BRIDGING THE COVERAGE-PARTICIPATION GAP: BEHAVIORAL DETERMINANTS OF CERVICAL CANCER SCREENING AMONG WOMEN IN ADJARA, GEORGIA. Georgian medical news 59.0 2 DETECTION OF HEPATITIS B AND C VIRAL INFECTION AMONG CHILDREN WITH ACUTE LEUKAEMIA. Georgian medical news 63.9 3 The impact of group cognitive behavioral therapy on stress and psychological adjustment among cigarette, e-cigarette, and hookah smokers. Journal of education and health promotion 67.14 4 Surgical outcomes of primary pediatric spinal cord tumors: A retrospective cohort. Surgical neurology international 70.0 5 Endoscopic spine surgery across the pediatric pathological spectrum: A systematic review of indications, techniques, and outcomes. Surgical neurology international 76.5 6 Microsurgical resection of a pure third ventricular craniopharyngioma through an interhemispheric transcallosal transforaminal approach. Surgical neurology international 66.3 7 Pediatric Pheochromocytoma With Rapid Cyclic Blood Pressure Fluctuations: A Case Report. Clinical case reports 49.9 8 Quantitative analysis of tumor perfusion via contrast-enhanced ultrasound to predict the neoadjuvant chemotherapy efficacy for children with hepatoblastoma. Journal of ultrasound 63.14 9 Surgical outcomes in pediatric patients with juvenile nasopharyngeal angiofibroma: a single-center retrospective analysis of 8 cases. International journal of pediatric otorhinolaryngology 63.9 10 Reactive oxygen species define leukemia stem cell identity in pediatric acute myeloid leukemia. Cancer letters 58.1 11 Papillary thyroid carcinoma in children: prevalence, morphology, molecular and cytogenetic characteristics, and prognostic determinants. Journal of pediatric endocrinology & metabolism : JPEM 69.2 12 The Lipid Switch: Ultra-High Dose Omega Fatty Acids Determine MYCN Neuroblastoma Fate and Implicate Substrate-Level Oxylipin Competition. ACS pharmacology & translational science 56.12 13 Managing skin-related adverse events during mirdametinib treatment for NF1-PNs: expert guidance from the ReNeu trial. Frontiers in oncology 80.36 14 CAR T cell-induced interferon gamma enhances MHC class I expression and sensitizes neuroblastoma to TCR-engineered T cell therapy. Frontiers in immunology 51.92 15 Pediatric Spinal Cord Astrocytoma With Granular Cell-Like Morphology and KIAA1549::BRAF Fusion. Neuropathology : official journal of the Japanese Society of Neuropathology 56.4 16 Can O-RADS Be Validated in Children Using a Malignant-Only Cohort? Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine 47.5 17 Continuous infusion of granulocyte colony-stimulating factor is associated with an advantage in neutrophil recovery in pediatric oncologic disorders. Cancer chemotherapy and pharmacology 64.3 18 Fertility-related knowledge and childbearing attitudes among female survivors of hematopoietic stem cell transplantation: a cross-sectional study. Journal of cancer survivorship : research and practice 61.1 19 Fibrolamellar Carcinoma in the Molecular Era: From DNAJB1::PRKACA Biology to Precision Therapeutic Strategies. Journal of gastrointestinal cancer 86.04 20 Focal periphyseal edema with atypical MRI features: Biopsy findings and imaging follow-up. Radiology case reports 56.0 21 CyberKnife SBRT plus lenvatinib and tislelizumab versus doublet systemic therapy for hepatocellular carcinoma with macrovascular invasion: A real-world IPTW-adjusted study. Clinical and translational radiation oncology 83.24 22 Single-session therapeutic plasma exchange as salvage therapy for pegaspargase-induced severe acute pancreatitis accompanied by multiple organ dysfunction in a pediatric patient with B-cell precursor acute lymphoblastic leukemia: a case report. BMC pediatrics 67.0 23 Evaluation of Regulatory B10 Cells in Common Variable Immunodeficiency Patients with and without Autoimmunity. Iranian journal of allergy, asthma, and immunology 59.1 24 An Unexpected Association of a Novel MYOF Variant with Generalized Myopathy and HAE-nl-C1-INH. Iranian journal of allergy, asthma, and immunology 38.6 25 Case Report: CBFA2T3::GLIS2-positive myeloid sarcoma with focal bone marrow involvement mimicking Ewing sarcoma in an infant. Frontiers in oncology 56.6 26 Extended genotype-phenotype spectrum of 17α-hydroxylase/17,20-lyase deficiency: a nine-case series featuring a novel mutation, suspected TART-like lesions, and multisystem involvement. Frontiers in endocrinology 54.5 27 Reninoma in an adolescent boy with negative selective renal vein sampling: a case report and review of the literature. Frontiers in endocrinology 50.3 28 Precision-based exercise protocols for children with cancer: a methodological approach from the European FORTEe research project. Frontiers in pediatrics 76.6 29 CircHIPK3 promotes the progression of B-cell acute lymphoblastic leukemia in children by binding to STAT3. Frontiers in pharmacology 54.3 30 Disease-specific heterogeneity of C-reactive protein across 21 hematologic disorders reflects divergent inflammatory and hematopoietic phenotypes. Frontiers in immunology 76.0 31 Exercise intervention for children with acute leukemia: a best evidence summary. Frontiers in pediatrics 82.2 32 Oral and maxillofacial malignancies in children and adolescents: a 17-year single-center retrospective study. World journal of pediatric surgery 66.9
PATIENT-FRIENDLY SUMMARY

[Survival analysis in hepatitis C cases aged ≥18 years in Yuxi City from 2005 to 2023].

For education only—not personal medical advice.

Before you continue

AI-assisted research information

Neurocompute uses AI to summarize scientific papers, interpret research signals, and suggest relevant reference links. AI-generated content can be incomplete, misleading, or wrong, and generated links may be irrelevant or unavailable.

Our reviewed outputs have performed strongly to date, but past accuracy is not a guarantee. Verify summaries, scores, claims, and links against the original publication before relying on them.

This platform is for research and education only. It does not provide medical advice, diagnosis, treatment recommendations, or clinical guidance.

Pediatric cancer research intelligence graphic
PEDIATRIC CANCER VISUAL SYSTEM

Open the Research Intelligence Map

Explore the active pediatric oncology analysis view.

Expand Intelligence View →
Full Pediatric cancer research intelligence graphic